Insider plans sale of 13,875 ZVRA shares

Zevra Therapeutics (symbol ZVRA) has a Form 144 filing indicating a planned insider sale of common stock.

Rhea-AI Filing Summary

Zevra Therapeutics (symbol ZVRA) has a Form 144 filing indicating a planned insider sale of common stock. The notice covers 13,875 common shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $122,932.50. The planned sale is listed for 01/30/2026 on the NASDAQ market. The shares were acquired from the issuer on 01/30/2026 as restricted stock units, in a non-cash transaction described as “N/A” for the nature of payment. The filing also states that the person selling the securities represents they are not aware of any undisclosed material adverse information about the issuer’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ZVRA Form 144 filing disclose?

The Form 144 for ZVRA discloses a planned sale of 13,875 common shares. These shares were acquired as restricted stock units from the issuer and are scheduled to be sold on NASDAQ through Morgan Stanley Smith Barney LLC, subject to Rule 144 conditions.

How many ZVRA shares are planned to be sold under this Form 144?

The filing reports a planned sale of 13,875 ZVRA common shares. These shares have an aggregate market value of $122,932.50 and are to be sold through Morgan Stanley Smith Barney LLC on or around January 30, 2026, according to the notice.

What is the aggregate market value of the ZVRA shares in this Form 144?

The Form 144 lists an aggregate market value of $122,932.50 for the 13,875 ZVRA common shares. This value is tied to the planned sale through Morgan Stanley Smith Barney LLC, with trading expected on NASDAQ on the approximate sale date provided.

When are the ZVRA shares expected to be sold according to the Form 144?

The notice states an approximate date of sale of 01/30/2026 for the 13,875 ZVRA common shares. The shares are expected to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC, consistent with Rule 144 requirements.

How were the ZVRA shares acquired that are being sold under Form 144?

The 13,875 ZVRA common shares were acquired as restricted stock units from the issuer on 01/30/2026. The filing lists the nature of payment as “N/A,” indicating no separate cash payment at acquisition, which is typical for equity compensation awards.

What does the Form 144 say about insider knowledge for the ZVRA sale?

The person for whose account the ZVRA shares are to be sold represents they do not know any undisclosed material adverse information about the issuer’s current or prospective operations, a standard certification required when filing a Form 144 notice of proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001945557
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ZEVRA THERAPEUTICS INC
SEC File Number	001-36913
Address of Issuer	1180 Celebration Boulevard, Suite 103 Celebration FLORIDA 34747
Phone	3219393416
Name of Person for Whose Account the Securities are To Be Sold	JOSHUA SCHAFER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13875	122932.50	56297535	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/30/2026	Restricted Stock Units	Issuer			13875	01/30/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were or will be acquired upon the vesting of restricted stock units during the period of 1/30/2026 through 1/31/2026
Date of Notice	01/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schafer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)